Table 2.

Population comparison of genotype and allele frequencies for calumenin among a patient population of northern European ethnicity with an indication for warfarin compared to a population of Spanish patients with an indication for acenocoumarol and a second population with non-ST elevation acute coronary syndrome.^*

				Allele Frequency
	Genotype Frequency			Major	Minor
Population	A/A	A/G	G/G	A	G
Marshfield warfarin-treated patients (N=491)*	0.26	0.45	0.29	0.49	0.51
Acenocoumarol-treated patients (Spanish population) N=20322	0.33	0.52	0.15	0.59	0.41
nSTACS (Spanish population) N=37423	0.33	0.51	0.16	0.59	0.41
HapMap CEU	0.43	0.43	0.13	0.65	0.35

^*Distribution among these populations of patients with requirements for anticoagulation is compared to the HapMap CEU, a Northern European population in Utah more similar to the Marshfield population in ethnic makeup.¹⁰ Whereas the two Spanish cohorts of acenocoumarol-exposed subjects exhibit nearly identical genotype frequency distribution, distributions between the Marshfield warfarin cohort and HapMap CEU population are significantly different (P=0.035).